DISCOUNT ZERTIFIKAT - ASTRAZENECA | Market Closed - Bid/Ask 11:20:35 2024-05-28 EDT | ||
| 121.2 EUR | -0.72% |
|
| Current month | +1.20% | ||
| 1 month | +4.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 121.2 | -0.72% |
| 24-05-24 | 122 | -0.15% |
| 24-05-23 | 122.2 | +0.10% |
| 24-05-22 | 122.1 | -0.06% |
| 24-05-21 | 122.2 | +0.88% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 11:20 am
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VZB |
| ISIN | DE000PC3VZB3 |
| Date issued | 2024-01-25 |
| Maturity | 2025-06-20 (388 Days) |
| Parity | 1 : 1 |
| Emission price | 110 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 122.3 € |
|---|---|
| Lowest since issue | 104.4 € |
| Spread | 0.05 € |
| Spread % | 0.04% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.55%
- Stock Market
- Certificates
- Certificat
